TLR2 activation causes no morbidity or cardiovascular failure, despite excessive systemic nitric oxide production

MLA

Peter Brouckaert, et al. “TLR2 Activation Causes No Morbidity or Cardiovascular Failure, despite Excessive Systemic Nitric Oxide Production.” Cardiovascular Research, vol. 100, June 2013, pp. 28–35. EBSCOhost, https://doi.org/10.1093/cvr/cvt168.

APA

Peter Brouckaert, Benjamin Vandendriessche, Benedicte Descamps, Tom Van Nieuwenhuysen, Christian Vanhove, Elke Rogge, Anje Cauwels, Jennyfer Bultinck, & Magdalena Sips. (2013). TLR2 activation causes no morbidity or cardiovascular failure, despite excessive systemic nitric oxide production. Cardiovascular Research, 100, 28–35. https://doi.org/10.1093/cvr/cvt168

Chicago

Peter Brouckaert, Benjamin Vandendriessche, Benedicte Descamps, Tom Van Nieuwenhuysen, Christian Vanhove, Elke Rogge, Anje Cauwels, Jennyfer Bultinck, and Magdalena Sips. 2013. “TLR2 Activation Causes No Morbidity or Cardiovascular Failure, despite Excessive Systemic Nitric Oxide Production.” Cardiovascular Research 100 (June): 28–35. doi:10.1093/cvr/cvt168.